Immunocorrelates of CAF family adjuvants
- PMID: 30396811
- DOI: 10.1016/j.smim.2018.10.003
Immunocorrelates of CAF family adjuvants
Abstract
The development of the CAF family adjuvant was initiated around 20 years ago when Statens Serum Institut was preparing its first generation protein based recombinant subunit vaccine against tuberculosis for clinical testing, but realized that there were no clinically relevant adjuvants available that would support the strong CMI response needed. Since then the aim for the adjuvant research at Statens Serum Institut has been to provide adjuvants with distinct immunogenicity profiles correlating with protection for any given infectious disease. Two of the adjuvants CAF01 and CAF09 are currently being evaluated in human clinical trials. The purpose of this review is to give an overview of the immunocorrelates of those CAF adjuvants furthest in development. We further aim at giving an overview of the mechanism of action of the CAF adjuvants.
Keywords: Adjuvant; CAF; Cationic; Immunocorrelates; MMG; TDB.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.Front Immunol. 2020 Sep 30;11:575504. doi: 10.3389/fimmu.2020.575504. eCollection 2020. Front Immunol. 2020. PMID: 33117374 Free PMC article.
-
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.Biochim Biophys Acta. 2005 Dec 10;1718(1-2):22-31. doi: 10.1016/j.bbamem.2005.10.011. Epub 2005 Nov 14. Biochim Biophys Acta. 2005. PMID: 16321607
-
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.Semin Immunol. 2018 Oct;39:14-21. doi: 10.1016/j.smim.2018.05.001. Epub 2018 May 23. Semin Immunol. 2018. PMID: 29801750 Review.
-
Toll like-receptor agonist Pam3Cys modulates the immunogenicity of liposomes containing the tuberculosis vaccine candidate H56.Med Microbiol Immunol. 2020 Apr;209(2):163-176. doi: 10.1007/s00430-020-00657-3. Epub 2020 Feb 4. Med Microbiol Immunol. 2020. PMID: 32020284 Free PMC article.
-
Liposome-based cationic adjuvant formulations (CAF): past, present, and future.J Liposome Res. 2009;19(1):2-11. doi: 10.1080/08982100902726820. J Liposome Res. 2009. PMID: 19515003 Review.
Cited by
-
Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.Eur J Pharm Biopharm. 2021 Aug;165:293-305. doi: 10.1016/j.ejpb.2021.05.020. Epub 2021 May 24. Eur J Pharm Biopharm. 2021. PMID: 34044110 Free PMC article.
-
Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines.PLoS Pathog. 2024 Jul 8;20(7):e1012220. doi: 10.1371/journal.ppat.1012220. eCollection 2024 Jul. PLoS Pathog. 2024. PMID: 38976694 Free PMC article.
-
Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics.Front Immunol. 2021 Oct 25;12:740117. doi: 10.3389/fimmu.2021.740117. eCollection 2021. Front Immunol. 2021. PMID: 34759923 Free PMC article. Review.
-
Microfluidic-prepared DOTAP nanoparticles induce strong T-cell responses in mice.PLoS One. 2020 Jan 24;15(1):e0227891. doi: 10.1371/journal.pone.0227891. eCollection 2020. PLoS One. 2020. PMID: 31978077 Free PMC article.
-
Liposomal delivery system/adjuvant for tuberculosis vaccine.Immun Inflamm Dis. 2023 Jun;11(6):e867. doi: 10.1002/iid3.867. Immun Inflamm Dis. 2023. PMID: 37382263 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
